Wall Street Futures Slip After Record Rally Fueled by Iran Peace Hopes and AMD Surge 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
S&P 500, Nasdaq Hit Record Highs as AI Stocks Rally and Strong Jobs Data Boost Confidence 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers 
US-Iran Ceasefire Under Pressure as Fresh Strait of Hormuz Clashes Shake Oil Markets 
Gold Prices Rise as Weaker Dollar and Iran Ceasefire Hopes Boost Safe-Haven Demand 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Oil Prices Rebound Slightly After Sharp Drop on Iran Deal Hopes 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
